GB9825946D0 - Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease - Google Patents
Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 proteaseInfo
- Publication number
- GB9825946D0 GB9825946D0 GBGB9825946.8A GB9825946A GB9825946D0 GB 9825946 D0 GB9825946 D0 GB 9825946D0 GB 9825946 A GB9825946 A GB 9825946A GB 9825946 D0 GB9825946 D0 GB 9825946D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- hepatitis
- protease
- virus
- inhibition
- pharmaceutical compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9825946.8A GB9825946D0 (en) | 1998-11-26 | 1998-11-26 | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease |
PCT/EP1999/009207 WO2000031129A1 (en) | 1998-11-26 | 1999-11-24 | Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease |
EP99972641A EP1144446A1 (en) | 1998-11-26 | 1999-11-24 | Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease |
CA002352493A CA2352493A1 (en) | 1998-11-26 | 1999-11-24 | Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease |
AU13871/00A AU764589B2 (en) | 1998-11-26 | 1999-11-24 | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease |
JP2000583956A JP2002530430A (en) | 1998-11-26 | 1999-11-24 | Pharmaceutical composition for inhibiting hepatitis C virus NS3 protease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9825946.8A GB9825946D0 (en) | 1998-11-26 | 1998-11-26 | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease |
Publications (1)
Publication Number | Publication Date |
---|---|
GB9825946D0 true GB9825946D0 (en) | 1999-01-20 |
Family
ID=10843111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB9825946.8A Ceased GB9825946D0 (en) | 1998-11-26 | 1998-11-26 | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1144446A1 (en) |
JP (1) | JP2002530430A (en) |
AU (1) | AU764589B2 (en) |
CA (1) | CA2352493A1 (en) |
GB (1) | GB9825946D0 (en) |
WO (1) | WO2000031129A1 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
NZ561851A (en) | 2002-04-11 | 2009-05-31 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
PT1654261E (en) | 2003-05-21 | 2008-01-18 | Boehringer Ingelheim Int | Hepatitis c inhibitor compounds |
TW201127828A (en) | 2003-09-05 | 2011-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
DE602004031645D1 (en) | 2003-09-22 | 2011-04-14 | Boehringer Ingelheim Pharma | MACROCYCLIC PEPTIDES WITH EFFECT AGAINST HEPATITIS C VIRUS |
CA2541634A1 (en) | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
US8187874B2 (en) | 2003-10-27 | 2012-05-29 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
CA2549851C (en) | 2004-01-21 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
AU2005212257A1 (en) | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
PT1719773E (en) | 2004-02-24 | 2009-06-03 | Japan Tobacco Inc | Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor |
EP1771454B1 (en) | 2004-07-20 | 2011-06-15 | Boehringer Ingelheim International GmbH | Hepatitis c inhibitor peptide analogs |
UY29016A1 (en) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
AU2006275413B2 (en) | 2005-08-02 | 2012-07-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
EP2357170A1 (en) | 2005-08-19 | 2011-08-17 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
AR055395A1 (en) | 2005-08-26 | 2007-08-22 | Vertex Pharma | INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS |
US7655394B2 (en) * | 2005-10-28 | 2010-02-02 | Boehringer Ingelheim International Gmbh | Hepatitis C virus NS2/3 activity assay |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
EP1951748B1 (en) | 2005-11-11 | 2013-07-24 | Vertex Pharmaceuticals, Inc. | Hepatitis c virus variants |
US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
CN102872461A (en) | 2007-05-04 | 2013-01-16 | 弗特克斯药品有限公司 | Combination therapy for the treatment of hcv infection |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
-
1998
- 1998-11-26 GB GBGB9825946.8A patent/GB9825946D0/en not_active Ceased
-
1999
- 1999-11-24 AU AU13871/00A patent/AU764589B2/en not_active Ceased
- 1999-11-24 CA CA002352493A patent/CA2352493A1/en not_active Abandoned
- 1999-11-24 EP EP99972641A patent/EP1144446A1/en not_active Withdrawn
- 1999-11-24 WO PCT/EP1999/009207 patent/WO2000031129A1/en active Search and Examination
- 1999-11-24 JP JP2000583956A patent/JP2002530430A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2000031129A1 (en) | 2000-06-02 |
CA2352493A1 (en) | 2000-06-02 |
AU764589B2 (en) | 2003-08-21 |
AU1387100A (en) | 2000-06-13 |
EP1144446A1 (en) | 2001-10-17 |
JP2002530430A (en) | 2002-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9825946D0 (en) | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease | |
AU2055301A (en) | Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease | |
SI1169339T1 (en) | Macrocyclic peptides inhibiting the hepatitis c virus ns3 protease | |
AU6371900A (en) | Lactam inhibitors of hepatitis c virus ns3 protease | |
GB9707659D0 (en) | Hepatitis C NS3 Protease inhibitors | |
IL191905A0 (en) | Inhibitors of serine proteases particularly hepatitis c virus ns3 protease, pharmaceutical compositions containing the same and the use thereof | |
AU2002230763A8 (en) | Inhibitors of hepatitis c virus ns3 protease | |
AU2933797A (en) | Synthetic inhibitors of hepatitis c virus ns3 protease | |
AU2001245356A1 (en) | Inhibitors of hepatitis c virus ns3 protease | |
HK1058047A1 (en) | Peptides as ns3-serine protease inhibitors of hepatitis c virus | |
IL141011A0 (en) | Hepatitis c inhibitor peptides | |
GB0107924D0 (en) | Inhibitor of hepatitis C virus NS3 protease | |
IL155842A0 (en) | Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus | |
IL141012A0 (en) | Hepatitis c inhibitor tripeptides | |
PL371324A1 (en) | Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c) | |
AU8063701A (en) | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | |
AU2001280640A1 (en) | Peptides as ns3-serine protease inhibitors of hepatitis c virus | |
AU2001277967A1 (en) | Peptides as ns3-serine protease inhibitors of hepatitis c virus | |
AU1324300A (en) | Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase | |
SI0932617T1 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease | |
EP1141255A4 (en) | Modified forms of hepatitis c virus ns3 protease | |
SI1326632T1 (en) | Proteasome inhibitors for the treatment of hepatitis virus infections | |
AU2002350322A1 (en) | Inhibitors of hepatitis c virus protease | |
DE19980730D2 (en) | Radioimmunopharmaceuticals for the treatment of hepatitis C |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |